NCT05444283 Genomic Predictors of Recurrent Pregnancy Loss
| NCT ID | NCT05444283 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yale University |
| Condition | Recurrent Pregnancy Loss |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2021-09-01 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2021-09-01 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The overall goals of this proposal are to determine the genetic architecture of recurrent pregnancy loss (RPL) and to discover genomic predictors of RPL.
Eligibility Criteria
Cohort A - Fetal Intolerome Cohort Inclusion Criteria: * Women with loss of a current singleton pregnancy at \< 20 0/7 weeks gestation, documented by ultrasonography or histopathological examination * History of one or more prior pregnancy losses * Euploid current pregnancy confirmed by karyotype, microarray, or STORK (Short-read Transpore Rapid Karyotyping) sequencing Note: A limited number of aneuploid losses will be included as part of the pilot phase Exclusion Criteria: * History of parental karyotype abnormalities * History of antiphospholipid antibody syndrome * Evidence of uncontrolled diabetes * Evidence of uncontrolled thyroid disease * History of autoimmune disease related to pregnancy loss (e.g., systemic lupus erythematosus, rheumatoid arthritis) * History of uterine anomalies * History of cervical insufficiency Cohort B - Maternal Effect Gene Cohort Inclusion Criteria: \- Women with a history of three or more pregnancy losses of unknown cause, with or without a liveborn child Exclusion Criteria: \- Known etiology for pregnancy loss
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05444283 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Recurrent Pregnancy Loss. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05444283 currently recruiting?
Yes, NCT05444283 is actively recruiting participants. Contact the research team at yong-hui.jiang@yale.edu for enrollment information.
Where is the NCT05444283 trial being conducted?
This trial is being conducted at Aurora, United States, New Haven, United States, Chicago, United States, Chicago, United States and 6 additional locations.
Who is sponsoring the NCT05444283 clinical trial?
NCT05444283 is sponsored by Yale University. The trial plans to enroll 500 participants.